ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2019
Strong sales growth during April; Zinzino based revenue increased 36% and the total group revenue with a total of 29% compared with the previous year.
The revenue for Zinzino's sales markets increased by 36% to SEK 53.4 (39.4) million due to strong growth foremost in Central Europe. Faun Pharma's external sales decreased by 8% and amounted to SEK 6.1 (6.6) million. Overall, the Group increased revenues by 29 % to SEK 59.5 (46.0) million compared with the previous year.
Accumulated income January - April increased by 24% to SEK 227.7 (183.7) million compared with the previous year.
Revenues distributed as follows:
|Regions,Msek||Apr-19||Apr-18||Change||YTD 2019||YTD 2018||Change|
|Europe Other Markets||17.4||5.3||229%||60.4||19.6||209%|
The sales figures are prepared according to IFRS. Adjustment for IFRS 15, income from customers has affected comparative figures.
For more information please contact:
Dag Bergheim Pettersen, CEO Zinzino, tel. +47 (0) 932 25 700
Pictures for free publication:
Marcus Tollbom, tel. +46 (0) 70-190 03 12
Erik Penser Bank Aktiebolag: +46 (0)8 463 83 00 Email: firstname.lastname@example.org
Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations
governing market abuse. The information was provided by the above contact person for publication at 10:00 the 14th of May, 2019.